Form 4: Turn Therapeutics Director Receives Stock Option Grant

Director Arthur F. Golden was granted 89,584 stock options in Turn Therapeutics Inc. as part of the company's incentive plan.

Summary

• Director Arthur F. Golden received a grant of 89,584 stock options on June 4, 2026.
• The options have an exercise price of $5.75 per share.
• The options vest in twelve equal monthly installments starting June 30, 2026, contingent on continued service.
• The grant was issued under the Issuer's 2025 Omnibus Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• Vesting schedule encourages director retention over the next year.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Future dilution of equity if options are exercised.
• Dependence on the director's continued service for full vesting.

Future Outlook

The options vest over a 12-month period, indicating a commitment to the director's ongoing role through mid-2027.

Management Comments

• The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure alignment between board members and shareholders, particularly in the biotechnology and therapeutics sector where long-term development cycles are common.

Comparison to Industry Standards

• The use of a 12-month vesting schedule for director options is relatively aggressive compared to the typical 3-4 year vesting schedules seen in broader industry standards for equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

Turn Therapeutics, TTRX, Form 4, Stock Options, Director Compensation, Insider Trading